Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
105,841,018
-
Number of holders
-
26
-
Total 13F shares, excl. options
-
1,733,782
-
Shares change
-
-125,488
-
Total reported value, excl. options
-
$9,586,000
-
Value change
-
-$1,340,161
-
Put/Call ratio
-
30%
-
Number of buys
-
10
-
Number of sells
-
-16
-
Price
-
$5.53
Significant Holders of SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) as of Q4 2021
38 filings reported holding SLS - SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share as of Q4 2021.
SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) has 26 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,733,782 shares
of 105,841,018 outstanding shares and own 1.64% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (654,562 shares), BlackRock Inc. (254,844 shares), GEODE CAPITAL MANAGEMENT, LLC (133,801 shares), MORGAN STANLEY (124,133 shares), Equitable Holdings, Inc. (102,000 shares), AMERIPRISE FINANCIAL INC (94,455 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (93,463 shares), CITADEL ADVISORS LLC (40,842 shares), STATE STREET CORP (37,468 shares), and BANK OF AMERICA CORP /DE/ (31,800 shares).
This table shows the top 26 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.